Compare Neurocrine Biosciences Inc (NBIX) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Boston Beer Company Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.39 (market cap $14.36B), while Boston Beer Company Inc trades at $170.35 (market cap $1.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.2× Boston Beer Company Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Boston Beer Company Inc for 59 Days on average.
| NBIX | SAM | |
|---|---|---|
Market Cap | $14.36B | $1.76B |
Volume | 1,237,180 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $260.05 |
52-Week Low | $123.10 | $161.08 |
Typical Hold Time | 23 Days | 59 Days |
Enterprise Value | $14.37B | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Boston Beer Company (SAM) trades at $171.33, up 1.89% with a bullish technical signal despite mixed earnings performance. The stock shows strong cash flow generation with $270M operating cash flow in 2025, but faces profitability challenges with negative net income margin of -3.64%. Recent developments include new product launches and marketing initiatives targeting younger demographics, while analyst consensus remains cautious with 72% hold ratings.
SAM presents a mixed investment case with attractive valuation metrics (P/E 22.7, P/S 0.94) offset by profitability concerns. Upside potential exists from innovation initiatives and brand investments, but investors face risks from volume declines and competitive pressures. The stock trades near consensus price target of $204.44, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
